Thorium Th 227 Trastuzumab Corixetan

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** A radioimmunoconjugate consisting of trastuzumab, a monoclonal antibody targeting the tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2), conjugated to the chelating agent corixetan, and labeled with the alpha-emitting radioisotope thorium Th 227, with potential antineoplastic activity. Upon administration of thorium Th 227 trastuzumab corixetan, the trastuzumab moiety targets and specifically binds to HER2 on tumor cells, thereby delivering a cytotoxic dose of alpha radiation to cells expressing HER2. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.

**Synonyms:** - 227Th Anti-HER2 Monoclonal Antibody BAY2701439 - 227Th Trastuzumab Corixetan - BAY 2701439 - BAY-2701439 - BAY2701439 - HER2-TTC - TRASTUZUMAB CORIXETAN THORIUM TH-227 - Th 227 Anti-HER2 Monoclonal Antibody BAY2701439 - Th-227-Anti-HER2 Monoclonal Antibody BAY2701439 - Thorium Th 227 Anti-HER2 Monoclonal Antibody BAY2701439 - Thorium Th 227 MOAB BAY2701439 - Thorium Th 227 Monoclonal Antibody BAY2701439 - Thorium-227 Anti-HER2 Monoclonal Antibody BAY2701439 - Trastuzumab Corixetan Thorium Th-227